StreetAlpha.app
Home › Stocks › ENTX

Entera Bio Ltd. (ENTX)

Healthcare
$3.00
▼ −0.66%
LAST CLOSE · NOV 17

Entera Bio develops oral tablet versions of injectable peptide and protein medicines, starting with an osteoporosis candidate. It last closed at $3.00 on Nov 17, down 0.66% on the day. The average 12-month price target from 2 analysts is $10.00 (+233.3% from the last close), with a high of $11.00 and a low of $9.00.

AI Auto Pilots
Is ENTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$29.4M
Free cash flow
−$15.8M
Valuation
Market cap
$522.4M
174.1M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$265.9M
At Sep 30
Shareholder equity
$274.3M
Shares outstanding
174.1M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $571K$571KFY2021FY2022: $134K$134KFY2022FY2023: $0$0FY2023FY2024: $181K$181KFY2024FY2025: $42K$42KFY2025

From ENTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Last report
Nov 6
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated ENTX in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 233.3% upside

Based on 2 analysts who set a price target on ENTX in the past 90 days. The average target is $10.00, with a high of $11.00 and a low of $9.00, compared with the last close of $3.00.

Low $9.00Avg $10.00High $11.00
Blue marker: last close $3.00
Highest target$11.00
Average target$10.00
Lowest target$9.00
Latest rating changes
GuggenheimInitiated
Sep 25Buy$11
Leerink PartnersInitiated
Sep 18Buy$9
DateFirmActionRatingPrice target
Sep 25GuggenheimInitiatedBuy$11
Sep 18Leerink PartnersInitiatedBuy$9
Loading…

Technical Analysis

ENTX · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 33% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $2.97, and the nearest resistance the Pivot at $3.03.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityLow, 6.1%/day
Key levels
$4.2052 week high+40.0%
$3.10Swing high (Aug 10)+3.3%
$3.0920 day average+3.0%
$3.06Pivot R1+2.0%
$3.03Pivot+1.0%
$3.00Last close
$2.97Pivot S1−1.0%
$2.9050 day average−3.3%
$2.90Swing low (Nov 5)−3.3%
$2.74100 day average−8.7%
$2.00200 day average−33.3%
$0.9152 week low−69.7%
Indicators
RSI (14)48.71Middle of its rangeNeutral
MACD0.06Below its signal lineBearish
Stochastic27.2Middle of its rangeNeutral
ADX (14)29.4Trending up
Williams %R-83.0Oversold below −80, overbought above −20Oversold
CCI (20)-44.1Oversold below −100, overbought above 100Neutral
Rate of change−1.6%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for ENTX

What happened before

See how ENTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ENTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ENTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ENTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

ENTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲38 buying vs 8 selling
  • ▲Held by funds +67.5 pts
  • ▲Funds holding +19
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4627+70.4%
In funds' top 1041+300.0%
Held by funds73.7%6.2%+67.5 pts
New / increased24 / 147 / 8+153.3%
Reduced / sold out4 / 46 / 6−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ENTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENTX is in one of them and how their past ENTX trades turned out.

ENTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENTX in an article yet. Here's the latest on the wider market.

About Entera Bio

Entera Bio is a clinical stage company developing oral tablet versions of peptide and protein medicines that are usually given by injection. Its most advanced product candidate, EB613, is an oral form of teriparatide being studied as a treatment for osteoporosis, a condition that weakens bones and raises fracture risk. The company's N-Tab platform is designed to help these medicines survive digestion and pass into the bloodstream. Entera is based in Jerusalem and targets patients and healthcare providers.

Headquarters
Jerusalem